Literature DB >> 17478469

Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis.

S Bernatsky1, M Hudson, S Suissa.   

Abstract

OBJECTIVES: To assess the risk of severe infections associated with the use of traditional disease-modifying anti-rheumatic drugs (DMARDs) and glucocorticoid agents in rheumatoid arthritis (RA).
METHODS: Our study was a case-control design nested within a cohort of 23 733 RA patients studied between 1 January 1980 and 31 December 2003. Matching on age and gender, and adjusting for comorbidity and physician use, conditional logistic regression was used to estimate the effect of specific drugs on the rate ratio (RR) for infections requiring hospitalization.
RESULTS: The risk for all infections requiring hospitalization appeared to be most elevated with current exposures to cyclophosphamide [RR: 3.26, 95% confidence interval (CI): 2.28-4.67] and systemic glucocorticoid agents (RR: 2.56, 95% CI: 2.29-2.85); azathioprine was associated with a moderate increased risk (RR: 1.52, 95% CI: 1.18-1.97). There was a suggestion of increased risk of pneumonia due to methotrexate (RR: 1.16, 95% CI: 1.02-1.33). The results were similar for the period before and after the introduction of anti-tumour necrosis factor (TNF) agents. The RR point estimate for anti-TNF agents suggested about a 2-fold increased risk for all infections, but the estimate was imprecise.
CONCLUSIONS: In this large cohort of RA patients, the most heightened risk of serious infections was seen with the use of glucocorticoid agents and immunosuppressive DMARDs. Assessments of infection risk related to newer and emerging therapies should carefully consider concomitant medication exposures, including traditional DMARDs and glucocorticoid therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17478469     DOI: 10.1093/rheumatology/kem076

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  83 in total

Review 1.  Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?

Authors:  Vasco C Romão; Aurea Lima; Miguel Bernardes; Helena Canhão; João Eurico Fonseca
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

Review 2.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

3.  Accuracy of pharmacy and coded-diagnosis information in identifying tuberculosis in patients with rheumatoid arthritis.

Authors:  Christina T Fiske; Marie R Griffin; Ed Mitchel; Timothy R Sterling; Carlos G Grijalva
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-04-24       Impact factor: 2.890

4.  Reducing periprosthetic joint infection: what really counts?

Authors:  Giuseppe Solarino; Antonella Abate; Giovanni Vicenti; Antonio Spinarelli; Andrea Piazzolla; Biagio Moretti
Journal:  Joints       Date:  2016-01-31

5.  Discontinuation of methotrexate therapy in older patients with newly diagnosed rheumatoid arthritis: analysis of administrative health databases in Québec, Canada.

Authors:  Sasha Bernatsky; Debbie Ehrmann Feldman
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

6.  Using Multiple Pharmacovigilance Models Improves the Timeliness of Signal Detection in Simulated Prospective Surveillance.

Authors:  Rolina D van Gaalen; Michal Abrahamowicz; David L Buckeridge
Journal:  Drug Saf       Date:  2017-11       Impact factor: 5.606

Review 7.  Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.

Authors:  Archana Jain; Jasvinder A Singh
Journal:  Immunotherapy       Date:  2013-03       Impact factor: 4.196

Review 8.  Infectious complications in juvenile idiopathic arthritis.

Authors:  Andrew Hurd; Timothy Beukelman
Journal:  Curr Rheumatol Rep       Date:  2013-05       Impact factor: 4.592

9.  Anti-inflammatory effects of licorice and roasted licorice extracts on TPA-induced acute inflammation and collagen-induced arthritis in mice.

Authors:  Ki Rim Kim; Chan-Kwon Jeong; Kwang-Kyun Park; Jong-Hoon Choi; Jung Han Yoon Park; Soon Sung Lim; Won-Yoon Chung
Journal:  J Biomed Biotechnol       Date:  2010-03-17

10.  Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.

Authors:  Matthew L Stoll; Alisa C Gotte
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.